Laboratory evaluation including novel diagnostic markers of inflammatory bowel disease

Crohn's Disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach

Volumn , Issue , 2012, Pages 277-285

  Dotan, Iris ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Activity; Anti glycan antibodies; CRP; ESR; IBD diagnosis; Stool markers

Indexed keywords

EID: 84940572965     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-0998-4_21     Document Type: Chapter

References (77)

1. Carvalho R, Abadon V, Dilworth HP, et al. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm Bowel Dis. 2006;12:258-62.
2. Sandborn WJ. Serologic markers in inflammatory bowel disease: state of the art. Rev Gastroenterol Disord. 2004;4:167-74.
3. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA related protein epitope. Infect Immun. 2000;68:1542-8.
4. Sendid B, Colombel JF, Jacquinot PM, et al. Specific antibody response to oligomannosidic epitopes in Crohn’s disease. Clin Diag Lab Immunol. 1996;3(2):219-26.
5. Austin G, Shaheen NJ, Sandler RS. Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am J Gastroenterol. 2006;101:413-6.
6. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology. 2001;120:1347-55.
7. Sutton CL, Kim J, Yaname A, et al. Identification of a novel bacterial sequence associated with Crohn’s disease. Gastroenterology. 2000;119:23-31.
8. Wei B, Huang T, Dalwaldi H, et al. Pseudomonas fluorescens encodes the Crohn’s disease associated I2 sequence and T-cell superantigen. Infect Immun. 2002;70:6567-75.
9. Lodes MJ, Cong Y, Elson CO, et al. Bacterial Flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-306.
10. Van den Bogaerde J, Kamm MA, Knight SC. Immune sensitization to food, yeast and bacteria in Crohn’s disease. Aliment Pharmacol Ther. 2001;15:1647-53.
11. Pang Z, Otaka K, Maoka T, Hidaka K, Ishijima S, Oda M, et al. Structure of b-glucan oligomer from laminarin and its effect on human monocytes to inhibit proliferation of U937 cells. Biosci Biotechnol Biochem. 2005;69: 553-8.
12. Palma AS, Feizi T, Zhang Y, Stoll MS, Lawson AM, Diaz-Rodriguez E, et al. Ligands for the b-glucan receptor, dectin-1, assigned using “designer” microarrays of oligosaccharide probes (neoglycolipids) generated from glu- can polysaccharides. J Biol Chem. 2006;281:5771-9.
13. Van Eijk M, van Roomen CP, Renkema GH, Bussink AP, Andrews L, Blommaart EF, et al. Characterization of human phagocyte-derived chitotriosidase, a component of innate immunity. Int Immunol. 2005;17:1505-12.
14. Seow CH, Stempak JM, Xu W, et al. Novel anti glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009;104(6):1426-34.
15. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004;126:414-24.
16. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left sided ulcerative colitis: results of a pilot study. Mayo Clin Proc. 1996;71:431-6.
17. Fleshner PF, Vasiliauskas EA, Kam LY, et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch anal anastomosis. Gut. 2001;49:671-7.
18. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-96.
19. Conrad A, Rutten C, Flogerzi B, Styner M, Goke B, Seibold F. Immune sensitization to yeast antigens in ASCA positive patients with Crohn’s disease. Inflamm Bowel Dis. 2004;10:97-105.
20. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101: 360-7.
21. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn’s disease patients and their unaffected relatives. Gastroenterology. 2007;132:576-86.
22. Mow WS, Landers CJ, Steinhart AH, Feagan BG, Croitoru K, Seidman E, et al. High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn’s disease: a pilot study. Dig Dis Sci. 2004;49:1280-6.
23. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn’s disease. Gastroenterology. 2005;128:2020-8.
24. Dotan I, Fishman S, Dgani Y, et al. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn’s disease. Gastroenterology. 2006;131:366-78.
25. Henckaerts L, Pierik M, Claes K, et al. Mutations in innate immune receptors modulate the serologic response to microbial antigens in patients with inflammatory bowel disease. Gastroenterology. 2006;130:A-585.
26. Eggena M, Cohavy O, Parseghian MH, et al. Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun. 2000;4(1):83-97.
27. Seibold F, Brandwein S, Simpson S, Terhorst C, Elson CO. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol. 1998;18(2):153-60.
28. Wiik A. Methods for the detection of anti-neutrophil cytoplasmic antibodies: recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results. Semin Immunopathol. 2001;23:217-29.
29. Sandbom WJ, Loftus EV, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2001;7(3):192-201.
30. Peeters M, Joosens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:730-4.
31. Duerr RH, Targan SR, Landers CJ, et al. Antineutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterology. 1991;100:1590-6.
32. Winter HS, Landers CJ, Winkelstein A, Wildrich A, Targan SR. Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr. 1994;125:707-11.
33. Seibold F, Slamettschka D, Gregor M, et al. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1994;107:523-6.
34. Oudkerk PM, Ellerbroek PM, Ridwan BU, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic antibodies and clinical parameters, medical and surgical treatment. Gut. 1993;34:46-50.
35. Quinton JF, Sendid B, Reumaux D, et al. Anti Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut. 1998;42:788-91.
36. Main J, Mckenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers’ yeast) in Crohn’s disease. BMJ. 1988;297:1105-6.
37. Barclay GR, McKenzie H, Pennington J, et al. The effect of dietary yeast on the activity of stable chronic Crohn’s disease. Scand J Gastroenterol. 1992;27 Suppl 3:196-200.
38. Vermeire S, Joosens S, Peeters M, et al. Comparative study of ASCA (Anti Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology. 2001;120:827-33.
39. Reumaux D, Sendid B, Poulain D, et al. Serological markers in inflammatory bowel diseases. Best Pract Res Clin Gastroenterol. 2003;17:19-35.
40. Damoiseaux JG, Bouten B, Linders AM, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies for inflammatory bowel disease: high prevalence in patients with celiac disease. J Clin Immunol. 2002;22:281-8.
41. Barta Z, Csipo I, Szabo GG. Seroreactivity against celiac disease. World J Gastroenterol. 2003;9:2308-12.
42. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-84.
43. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn’s disease. Gastroenterology. 2006;130:1069-77.
44. Vermeire S, Peeters M, Vlietinck R, et al. Anti Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8-15.
45. Sendid B, Quinton IF, Gwenaele C, et al. Anti Saccharomyces cerevisiae mannan antibodies in familial Crohn’s disease. Am J Gastroenterol. 1998;93:1306-10.
46. Sutton CL, Yang H, Li Z, et al. Family expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s disease. Gut. 2000;46:58-63.
47. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232-6.
48. Mei M, Targan SR, Landers CJ, et al. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn’s disease. Gastroenterology. 2006;130(4):1078-85.
49. Joosens S, Colombel JF, Landers C, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006;55:1667-8.
50. Spivak J, Landers CJ, Vasiliauskas EA, et al. Antibodies to I2 predict clinical response to fecal diversion in Crohn’s disease. Inflamm Bowel Dis. 2006;12:1122-30.
51. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410:1099-103.
52. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol. 2001;167:1882-5.
53. Ferrante M, Pierik M, Henckaerts L, et al. A panel of anti-glycan antibodies (gASCA, ALCA, ACCA and AMCA) in the diagnosis and differential diagnosis of IBD. Gastroenterology. 2006;130:A200.
54. Joosens S, Reinisch W, Vermeire S, et al. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology. 2002;122:1242-7.
55. Thjodleifsson B, Sigthorsson G, Cariglia N, et al. Subclinical intestinal inflammation: an inherited abnormality in Crohn’s disease relatives? Gastroenterology. 2003;124:1728-37.
56. Tromm A, Tromm CD, Huppe D, et al. Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn’s disease. Scand J Gastroenterol. 1992;27:774-8.
57. Sachar DB, Luppescu NE, Bodian C, et al. Erythrocyte sedimentation as a measure of Crohn’s disease activity: opposite trends in ileitis versus olitis. J Clin Gastroenterol. 1990;12:643-6.
58. Sachar DB, Smith H, Chan S, et al. Erythrocytic sedimentation rate as assure of clinical activity in inflammatory bowel disease. J Clin Gastroenterol. 1986;8:647-50.
59. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12.
60. Tall AR. C-reactive protein reassessed. N Engl J Med. 2004;350:1450-2.
61. Pepys MB. C-reactive protein fifty years on. Lancet. 1981;1:653-7.
62. Consigny Y, Modigliani R, Colombel JF, Dupas JL, Mary JY. Biological markers of short term relapse in Crohn’s disease (CD). Gastroenterology. 2001;20:A53.
63. Zilberman L, Maharshak M, Arbel Y, et al. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn’s disease and ulcerative colitis. Digestion. 2006;73:205-9.
64. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383-95.
65. Rpseth AG, Fagerhol MK, Aadland E, Schj0nsby H. Assessment of the neutrophil dominating protein calprotec- tin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-8.
66. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
67. Fagan EA, Dyck RF, Maton PN, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982;12:351-9.
68. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-eactiveprotein (CRP) with clinical, radiographic, and endoscopic activity in inflammatory bowel disease (IBD). Inflamm Bowel Dis. 2005;11:707-12.
69. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362-6.
70. Baveye S, Elass E, Mazurier J, et al. Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process. Clin Chem Lab Med. 1999;37:281-6.
71. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica. 1995;80:252-67.
72. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:414-22.
73. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40-6.
74. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008;14:32-9.
75. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162-9.
76. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-14.
77. Sidhu R, Wilson P, Wright A, et al. Faecal lactoferrin - a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther. 2010;31:1365-70.